CA3096821A1 - Methods of improving cardiovascular function and treating cardiovascular disease using a recombinant ectonucleotide pyrophosphatase phosphodiesterase (npp1) - Google Patents

Methods of improving cardiovascular function and treating cardiovascular disease using a recombinant ectonucleotide pyrophosphatase phosphodiesterase (npp1) Download PDF

Info

Publication number
CA3096821A1
CA3096821A1 CA3096821A CA3096821A CA3096821A1 CA 3096821 A1 CA3096821 A1 CA 3096821A1 CA 3096821 A CA3096821 A CA 3096821A CA 3096821 A CA3096821 A CA 3096821A CA 3096821 A1 CA3096821 A1 CA 3096821A1
Authority
CA
Canada
Prior art keywords
fusion protein
npp1
seq
patient
hsnpp1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3096821A
Other languages
English (en)
French (fr)
Inventor
Tayeba KHAN
Andre Marozsan
Kim ASKEW
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Inozyme Pharma Inc
Original Assignee
Inozyme Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inozyme Pharma Inc filed Critical Inozyme Pharma Inc
Publication of CA3096821A1 publication Critical patent/CA3096821A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/04—Phosphoric diester hydrolases (3.1.4)
    • C12Y301/04001—Phosphodiesterase I (3.1.4.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
CA3096821A 2017-09-27 2018-09-26 Methods of improving cardiovascular function and treating cardiovascular disease using a recombinant ectonucleotide pyrophosphatase phosphodiesterase (npp1) Pending CA3096821A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762563829P 2017-09-27 2017-09-27
US62/563,829 2017-09-27
PCT/US2018/052795 WO2019067502A1 (en) 2017-09-27 2018-09-26 METHODS FOR IMPROVING CARDIOVASCULAR FUNCTION AND TREATING CARDIOVASCULAR DISEASE USING RECOMBINANT ECTO-NUCLEOTIDE PYROPHOSPHATASE / PHOSPHODIESTERASE

Publications (1)

Publication Number Publication Date
CA3096821A1 true CA3096821A1 (en) 2019-04-04

Family

ID=63858139

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3096821A Pending CA3096821A1 (en) 2017-09-27 2018-09-26 Methods of improving cardiovascular function and treating cardiovascular disease using a recombinant ectonucleotide pyrophosphatase phosphodiesterase (npp1)

Country Status (5)

Country Link
US (2) US12134790B2 (https=)
EP (1) EP3687565A1 (https=)
JP (3) JP7511469B2 (https=)
CA (1) CA3096821A1 (https=)
WO (1) WO2019067502A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11364284B2 (en) 2016-06-16 2022-06-21 Inozyme Pharma, Inc. Methods of treating myointimal proliferation
EP3687565A1 (en) 2017-09-27 2020-08-05 Alexion Pharmaceuticals, Inc. Methods of improving cardiovascular function and treating cardiovascular disease using a recombinant ectonucleotide pyrophosphatase phosphodiesterase (npp1)
CN116406281A (zh) * 2020-05-27 2023-07-07 依诺兹梅制药公司 用于治疗外周动脉疾病的组合物和方法
KR20230047334A (ko) * 2020-05-27 2023-04-07 이노자임 파마, 인코포레이티드 혈관 평활근 세포 증식을 억제하기 위한 조성물 및 방법
IL298853A (en) * 2020-06-09 2023-02-01 Inozyme Pharma Inc Soluble enpp1 or enpp3 proteins and uses thereof
WO2023049864A1 (en) * 2021-09-24 2023-03-30 Inozyme Pharma, Inc. Lyophilized enpp1 polypeptide formulations and uses thereof

Family Cites Families (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US6267964B1 (en) 1989-08-01 2001-07-31 Affibody Technology Sweden Ab Stabilized protein or peptide conjugates able to bond albumin having extended biological half-lives
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
GB8918616D0 (en) 1989-08-15 1989-09-27 Univ Glasgow Herpes simplex virus type 1 mutant
US20020164782A1 (en) 1999-02-10 2002-11-07 Gregory Richard J. Adenovirus vectors for gene therapy
JPH04292169A (ja) 1991-03-19 1992-10-16 Sekisui Chem Co Ltd ハイブリッド型人工膵臓
US5418618A (en) 1992-03-09 1995-05-23 Mita Industrial Co., Ltd. Tone processing method for forming a halftone image
US5804413A (en) 1992-07-31 1998-09-08 University Of Pittsburgh Of The Commonwealth System Of Higher Education Herpes simplex virus strains for gene transfer
EP0719434B1 (de) 1993-09-15 1997-07-23 Océ Printing Systems GmbH Anordnung zur erzeugung eines rasterbildes auf einem lichtempfindlichen aufzeichunungsträger
AU1518595A (en) 1994-01-14 1995-08-01 Genentech Inc. Antagonists to insulin receptor tyrosine kinase inhibitor
GB9415319D0 (en) 1994-07-29 1994-09-21 Medical Res Council HSV viral vector
US5846782A (en) 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US6001650A (en) 1995-08-03 1999-12-14 Avigen, Inc. High-efficiency wild-type-free AAV helper functions
US6825396B2 (en) 1996-06-12 2004-11-30 Board Of Trustees Operating Michigan State University Methods for tissue specific synthesis of protein in eggs of transgenic hens
CA2280957A1 (en) 1997-02-14 1998-08-20 Leslie Orgel Methods and compositions for delivery of therapeutic agents to bone tissue employing conjugates of negatively charged peptide oligomers with therapeutic agents
US6156303A (en) 1997-06-11 2000-12-05 University Of Washington Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom
AU8605598A (en) 1997-07-31 1999-02-22 University Of Pittsburgh Targeted hsv vectors
US20040019923A1 (en) 1997-10-16 2004-01-29 Ivarie Robert D. Exogenous proteins expressed in avians and their eggs
DK1023442T3 (da) 1997-10-16 2011-03-14 Univ Georgia Transgenetiske fugle og fremstilling af proteiner
US5932465A (en) 1997-10-16 1999-08-03 Icos Corporation Phosphodiesterase 8A
EP1032662B1 (en) 1997-11-07 2006-03-08 Trillium Therapeutics Inc. Methods and compositions for immunomodulation
US6894022B1 (en) 1998-08-27 2005-05-17 Eidgenossische Technische Hochschule Zurich Growth factor modified protein matrices for tissue engineering
US6272859B1 (en) 1998-10-02 2001-08-14 Caterpillar Inc. Device for controlling a variable geometry turbocharger
US6043056A (en) 1998-11-06 2000-03-28 Incyte Pharmaceuticals, Inc. Cell surface glycoproteins
AU1801899A (en) 1998-12-03 2000-06-19 Histatek, Llc Small peptides and methods for treatment of asthma and inflammation
PT1916258E (pt) 1999-08-09 2014-07-29 Genzyme Corp Aumento da expressão de uma sequência nucleotídica heteróloga de cadeia simples a partir de vectores virais recombinantes por concepção da sequência de maneira que esta forme pares de bases intracadeia
JP3983449B2 (ja) 1999-10-15 2007-09-26 株式会社リコー パルス幅変調回路、光書き込み装置及び画像形成装置
EP2180054A1 (en) 1999-12-24 2010-04-28 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
WO2001062977A2 (en) 2000-02-23 2001-08-30 Pxe International, Inc. Methods and composition for diagnosing and treating pseudoxanthoma elasticum and related conditions
JP2001274989A (ja) 2000-03-27 2001-10-05 Ricoh Co Ltd 画像処理装置及び画像処理方法並びにプリンタ出力装置
DE20121960U1 (de) 2000-04-06 2004-01-15 Epigenomics Ag Nukleinsäuren für die Diagnose von mit Metastase assoziierten Krankheiten
WO2002012182A1 (fr) 2000-08-08 2002-02-14 Chugai Seiyaku Kabushiki Kaisha Derives de 3-methyl-20-epi-vitamine d
WO2002039994A2 (en) 2000-11-20 2002-05-23 University Of Kansas Medical Center Methods for the treatment and prevention of urinary stone disease
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
US20020108132A1 (en) 2001-02-02 2002-08-08 Avigenics Inc. Production of a monoclonal antibody by a transgenic chicken
US7211395B2 (en) 2001-03-09 2007-05-01 Dyax Corp. Serum albumin binding moieties
WO2002092020A2 (en) 2001-03-23 2002-11-21 The Burnham Institute Compositions and methods for modulating bone mineral deposition
US7888372B2 (en) 2001-03-23 2011-02-15 National Institutes Of Health (Nih) Compositions and methods for modulating bone mineral deposition
US20030191073A1 (en) 2001-11-07 2003-10-09 Challita-Eid Pia M. Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer
WO2003016475A2 (en) 2001-08-14 2003-02-27 The General Hospital Corporation Nucleic acid and amino acid sequences involved in pain
EP1438401B1 (en) 2001-09-18 2011-06-15 Synageva BioPharma Corp. Production of a transgenic avian by cytoplasmic injection
CA2462653C (en) 2001-11-07 2016-06-07 Aya Jakobovits Nucleic acid and corresponding protein entitled 161p2f10b useful in treatment and detection of cancer
US6875588B2 (en) 2001-11-30 2005-04-05 Avigenics, Inc. Ovomucoid promoter and methods of use
US7294507B2 (en) 2001-11-30 2007-11-13 Avigenics, Inc. Ovomucoid promoters and methods of use
US7335761B2 (en) 2001-11-30 2008-02-26 Avigenics, Inc. Avian gene expression controlling regions
US7858297B2 (en) 2001-12-18 2010-12-28 Centre National De La Recherche Scientifique Cnrs Chemokine-binding protein and methods of use
AU2003213246A1 (en) 2002-02-21 2003-09-09 University Of Virginia Patent Foundation Bone targeting peptides
US20080108560A1 (en) 2002-03-05 2008-05-08 Eli Lilly And Company Heterologous G-Csf Fusion Proteins
EP1576172A2 (en) 2002-06-21 2005-09-21 Dyax Corporation Serum protein-associated target-specific ligands and identification method therefor
US20040224893A1 (en) 2003-05-06 2004-11-11 Li-Hsien Wang Methods of using IL-1 antagonists to treat neointimal hyperplasia
US20050090001A1 (en) 2003-10-07 2005-04-28 Parker Stephen H. Cell lines and methods for producing proteins
ES2567634T3 (es) 2004-02-09 2016-04-25 Human Genome Sciences, Inc. Proteínas de fusión de albúmina
DE602005027461D1 (de) 2004-04-21 2011-05-26 Enobia Pharma Inc Konjugate zur zuführung an knochen und verfahren zu deren verwendung beim hinführen von proteinen zum knochen
US9055984B2 (en) 2004-04-21 2015-06-16 DePuy Synthes Products, Inc. Sternal reconstruction system
US20050287284A1 (en) 2004-06-28 2005-12-29 Shukla Triveni P Processed meats comprising dietary fiber gel
US20090142347A1 (en) 2004-09-29 2009-06-04 The Burnham Institute For Medical Research Tissue-Nonspecific Alkaline Phosphatase (TNAP): a Therapeutic Target for Arterial Calcification
WO2006050211A2 (en) 2004-10-28 2006-05-11 University Of Pittsburgh Of The Commonwealth System Of Higher Education Peripherally delivered glutamic acid decarboxylase gene therapy for spinal cord injury pain
US8110660B2 (en) 2004-11-19 2012-02-07 Ono Pharmaceutical Co., Ltd. Soluble ENPP4 protein
GB0426397D0 (en) 2004-12-01 2005-01-05 Health Prot Agency Fusion proteins
EP1777906A1 (en) 2005-06-09 2007-04-25 Matsushita Electric Industrial Co., Ltd. Amplitude error compensating apparatus and orthogonality error compensating apparatus
JP5199077B2 (ja) 2005-06-10 2013-05-15 アルタス ファーマシューティカルズ インコーポレイテッド シュウ酸オキシダーゼ結晶の投与による、シュウ酸塩濃度を低下させるための方法
EP1736553A1 (en) 2005-06-17 2006-12-27 Centre National De La Recherche Scientifique ENPP1 (PC-1) gene haplotype associated with the risk of obesity and type 2 diabetes and their applications
US20090180989A1 (en) 2005-10-05 2009-07-16 Synageva Biopharma Corp. Compositions and methods for delivering nucleotide sequences to vertebrates
US11039942B2 (en) 2006-06-13 2021-06-22 Sino Medical Sciences Technology Inc. Drug eluting stent and method of use of the same for enabling restoration of functional endothelial cell layers
PT2046373E (pt) 2006-08-02 2013-05-06 Althea Technologies Inc Oxalato descarboxilase cristalizada e métodos de utilização
CN101646689A (zh) 2006-09-08 2010-02-10 埃博灵克斯股份有限公司 具有长半衰期的血清清蛋白结合蛋白
EP2097533B9 (en) 2006-11-28 2010-12-22 Proyecto de Biomedicina Cima, S.L. Viral vector and uses thereof
US20080273206A1 (en) 2007-04-23 2008-11-06 University Of South Carolina Biomimetic Mineralization Method and System
PT2662448T (pt) 2007-05-11 2017-03-29 Alexion Pharma Inc Fosfatase alcalina dirigida ao osso, kits e métodos para a utilização da mesma
US20100184672A1 (en) 2007-06-18 2010-07-22 Mccarty Owen J T Protein c for use in maintaining hemostasis
WO2009030254A1 (en) 2007-09-04 2009-03-12 Curevac Gmbh Complexes of rna and cationic peptides for transfection and for immunostimulation
GB0803352D0 (en) 2008-02-22 2008-04-02 Ntnu Technology Transfer As Oligopeptidic compounds and uses thereof
AR071885A1 (es) 2008-05-23 2010-07-21 Wyeth Corp Proteinas de union al receptor de interleuquina 21
JP4888439B2 (ja) 2008-05-30 2012-02-29 ブラザー工業株式会社 画像読取装置および原稿サイズ決定プログラム
CA2788682C (en) 2010-02-05 2019-03-05 The University Of North Carolina At Chapel Hill Compositions and methods for enhanced parvovirus transduction
ES2628841T3 (es) 2010-03-12 2017-08-04 Alexion Pharmaceuticals, Inc. Proteínas de fusión npp1
KR101772366B1 (ko) 2011-03-11 2017-08-28 알렉시온 파마슈티칼스, 인코포레이티드 Ｎｐｐ１ 융합 단백질
JP2014509617A (ja) 2011-03-29 2014-04-21 ベタ−セル エンフェー 治療薬のカプセル化方法、およびその使用
WO2013074615A1 (en) 2011-11-14 2013-05-23 Yale University Compositions and methods for modulating coagulation
KR20150103269A (ko) 2013-01-04 2015-09-09 렘펙스 파머수티클스 인코퍼레이티드 보론산 유도체 및 그의 치료적 용도
WO2014126965A2 (en) 2013-02-13 2014-08-21 Yale University Compositions and methods for treating pathological calcification and ossification
US20160184458A1 (en) 2013-03-14 2016-06-30 Shire Human Genetic Therapies, Inc. Mrna therapeutic compositions and use to treat diseases and disorders
CN105378075B (zh) 2013-03-15 2022-04-05 Atyr 医药公司 组氨酰-trna合成酶-fc缀合物
ES2523016B1 (es) 2013-05-20 2015-09-09 3P Biopharmaceuticals Vectores alfavirales y líneas celulares para la producción de proteínas recombinantes
KR102456567B1 (ko) 2013-08-09 2022-10-19 알데릭스, 인코포레이티드 인산염 수송을 억제하기 위한 화합물 및 방법
CA2924259C (en) 2013-09-19 2021-12-21 Universitatsspital Basel Artificial vascular graft
DK3107562T3 (da) 2014-02-19 2019-12-16 Bioasis Technologies Inc P97-ids-fusionsproteiner
GB2526339A (en) 2014-05-21 2015-11-25 Imp Innovations Ltd Lentiviral vectors
CA2960912A1 (en) 2014-09-16 2016-03-24 Universitat Autonoma De Barcelona Adeno-associated viral vectors for the gene therapy of metabolic diseases
EP3234116B1 (en) 2014-12-19 2021-09-08 Alexion Pharmaceuticals, Inc. Methods of treating tissue calcification
US10926006B2 (en) 2015-02-26 2021-02-23 Remodeless Cv Ltd Drug eluting stent
KR20250078598A (ko) 2015-05-19 2025-06-02 예일 유니버시티 병리학적 석회화 병태를 치료하기 위한 조성물, 및 이의 사용 방법
FI3373980T3 (fi) 2015-11-12 2025-07-10 The Res Institute At Nationwide Childrens Hospital Menetelmiä lihasdystrofian hoitamiseksi
WO2017087936A1 (en) 2015-11-20 2017-05-26 Yale University Compositions for treating ectopic calcification disorders, and methods using same
EP3452101A2 (en) 2016-05-04 2019-03-13 CureVac AG Rna encoding a therapeutic protein
US11364284B2 (en) 2016-06-16 2022-06-21 Inozyme Pharma, Inc. Methods of treating myointimal proliferation
BR112019002355A2 (pt) 2016-08-05 2019-07-16 Yale University composições e métodos para prevenção de acidente vascular cerebral em pacientes pediátricos com anemia falciforme
MX2019009812A (es) 2017-02-27 2019-10-14 Shattuck Labs Inc Proteinas quimericas basadas en tigit y light.
EP3687565A1 (en) 2017-09-27 2020-08-05 Alexion Pharmaceuticals, Inc. Methods of improving cardiovascular function and treating cardiovascular disease using a recombinant ectonucleotide pyrophosphatase phosphodiesterase (npp1)
JP2021523139A (ja) 2018-05-08 2021-09-02 イエール ユニバーシティ 腎石症の進行を遅らせるための組成物および方法

Also Published As

Publication number Publication date
US12134790B2 (en) 2024-11-05
JP2020535161A (ja) 2020-12-03
EP3687565A1 (en) 2020-08-05
JP2025023189A (ja) 2025-02-14
US20250019677A1 (en) 2025-01-16
JP2023033610A (ja) 2023-03-10
WO2019067502A1 (en) 2019-04-04
JP7598960B2 (ja) 2024-12-12
JP7511469B2 (ja) 2024-07-05
US20200263153A1 (en) 2020-08-20

Similar Documents

Publication Publication Date Title
US20250019677A1 (en) Methods of improving cardiovascular function and treating cardiovascular disease using a recombinant ectonucleotide pyrophosphatase phosphodiesterase (npp1)
ES2356286T3 (es) Composiciones para inhibir la proteincinasa c-alfa para el tratamiento de diabetes mellitus.
USRE49529E1 (en) Methods of treating tissue calcification
RU2457854C2 (ru) Длительное высвобождение нейрегулина для улучшения сердечной функции
WO2009156481A1 (en) Pegylated bnp
CN110087666B (zh) 用于治疗糖尿病、高血压和高胆固醇血症的组合物和方法
CN115867306A (zh) ActRII蛋白以及在治疗毛细血管后肺高压中的用途
CN109069595A (zh) 标靶医疗性溶酶体酵素融合蛋白质、其相关调配物与用途
KR20230141958A (ko) 개선된 치료 지수를 위한 플라스민-내성 펩티드
AU2017213440A1 (en) Methods for repairing tissue damage using protease-resistant mutants of stromal cell derived Factor-1
CN105407909A (zh) 用于治疗高血糖症的载脂蛋白a-i源性肽
CN112585159A (zh) 神经调节蛋白多肽片段及其用途
TWI737972B (zh) 心肌再灌流的方法及套组與減緩或減少心肌再灌流損傷的方法
JP2022516199A (ja) ニューレグリンを用いて心筋損傷を予防、治療、又は緩和するための方法及びそのための組成物
HK40116513A (en) Methods of treating tissue calcification
KR20260006552A (ko) Igf-1 키메라 단백질을 이용한 치료 방법
US20230173029A1 (en) Treatment of cardiac remodelling
EA049479B1 (ru) БЕЛКИ ActRII И ПРИМЕНЕНИЕ В ЛЕЧЕНИИ ПОСТКАПИЛЛЯРНОЙ ЛЕГОЧНОЙ ГИПЕРТЕНЗИИ
HK40070846B (en) Soluble npp1 for use in a method for treating pseudoxanthoma elasticum
HK40070846A (en) Soluble npp1 for use in a method for treating pseudoxanthoma elasticum
HK1196944A (en) Methods for repairing tissue damage using protease-resistant mutants of stromal cell derived factor-1
HK1196944B (en) Methods for repairing tissue damage using protease-resistant mutants of stromal cell derived factor-1

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20230920

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20240913

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240918

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240918

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240918

B12 Application deemed to be withdrawn, abandoned or lapsed

Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B12-B303 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO AN EXAMINER'S REQUISITION

Effective date: 20250113

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250704

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250704

R11 Change to the name of applicant or owner or transfer of ownership requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R11-R127 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER RECORDAL REQUEST OR RESPONSE

Effective date: 20260102

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260113

R14 Transfer of ownership recorded

Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R14-R129 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260114